Stella Diagnostics (Stella Diagnostics) Accounts Payable : $0.15 Mil (As of Sep. 2023)

View and export this data going back to 2021. Start your Free Trial

What is Stella Diagnostics Accounts Payable?

Stella Diagnostics's Accounts Payable for the quarter that ended in Sep. 2023 was $0.15 Mil.

Stella Diagnostics's quarterly Accounts Payable stayed the same from . 20 ($0.00 Mil) to Sep. 2022 ($0.00 Mil) but then increased from Sep. 2022 ($0.00 Mil) to Sep. 2023 ($0.15 Mil).

Stella Diagnostics Accounts Payable Historical Data

The historical data trend for Stella Diagnostics's Accounts Payable can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Stella Diagnostics Accounts Payable Chart

Stella Diagnostics Annual Data

Trend

Accounts Payable

Stella Diagnostics Quarterly Data
	Sep22	Sep23
Accounts Payable	-	0.15

Stella Diagnostics Accounts Payable Calculation

Accounts Payable represents any money that a company owes its suppliers for goods and services purchased on credit and is expected to pay within the next year or operating cycle.

Stella Diagnostics Accounts Payable Related Terms

Thank you for viewing the detailed overview of Stella Diagnostics's Accounts Payable provided by GuruFocus.com. Please click on the following links to see related term pages.

Stella Diagnostics (Stella Diagnostics) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » Stella Diagnostics Inc (OTCPK:SLDX) » Definitions » Accounts Payable

Comparable Companies

Traded in Other Exchanges

N/A

Address

50 West Broadway, Suite 300, Salt Lake City, UT, USA, 84104

Website

https://www.stelladx.com

Stella Diagnostics Inc is a molecular diagnostics-based organization focused on improving patient management strategies for people living with severe esophageal disease. It is developing first-line diagnostic tools that provide superior molecular information for providers as compared to the current standard screening protocols.